Over the course of the year so far Halberd Corporation (OTCMKTS:HALB) has emerged as one of the more interesting companies for the sort of research that it has conducted with regard to a wide range of ailments. The company was in the news yesterday after it made an announcement with regards to one of its latest research efforts.
The company announced that its researchers had been successful in demonstrating the capability of precisely controlling the extent of PD-1 in human blood serum. The whole thing was demonstrated in laboratory in-vitro testing.
In this context, it is important for investors to perhaps have a better idea about what PD-1 actually is. PD-1 is actually a T-Cell protein that can be deployed by the tumor cells to flummox the immune system of the body into permitting the tumor to grow further. Halberd has come up with its proprietary extracorporeal process and the process can be used for the purpose of eliminating PD-1 when it is operated on blood serum.
Once that is eliminated, the immune system of the body can then attack the tumor and eliminate it in due course. It goes without saying that the development was a significant one for the company and it is going to be fairly interesting to see how investors react to it through the rest of the week.
It should be noted that the reason it is a momentous achievement for Halberd is the fact that most of the immunotherapy treatments that are being researched by many companies at this point are trying to achieve exactly this.
On the other hand, the extracorporeal process can also help in restoring the healthy PD-1 in a human body within a matter of hours. In case of other treatments, the restoration can process can take days or months.
